Last updated: February 23, 2026
What is the drug associated with NDC 00597-0115?
NDC 00597-0115 corresponds to Lomitapide, oral capsule. It is approved by the FDA for the treatment of homozygous familial hypercholesterolemia (HoFH). Developed by Amryt Pharma, Lomitapide acts as a microsomal triglyceride transfer protein (MTP) inhibitor, reducing LDL cholesterol levels.
Market Landscape
Indication and Patient Population
Homozygous familial hypercholesterolemia (HoFH) affects approximately 1 to 2 per million globally, with higher prevalence in certain populations (e.g., Lebanon, South Africa). Standard care involves LDL apheresis and high-intensity statins, but Lomitapide provides an alternative for refractory cases.
Market Size
- Estimated global HoFH prevalence: 5,000 to 9,000 patients.
- In the U.S.: approximately 650 to 1,300 patients diagnosed with HoFH.
- Market penetration is limited by the rarity of the condition and the high cost of therapy.
Competitor Drugs
- Mipomersen (Kynamro)
- PCSK9 inhibitors (e.g., Alirocumab, Evolocumab)—off-label for HoFH, with variable efficacy.
- Lomitapide is distinguished by its oral administration and efficacy in reducing LDL cholesterol.
Current Market Dynamics
Lomitapide's sales are constrained by patient access issues, high price, and safety concerns (gastrointestinal side effects, hepatotoxicity). Recently, generic competition is limited due to patent protections extending into the mid-2020s.
Price Analysis
Current Pricing (as of 2023)
- Wholesale Acquisition Cost (WAC): Approximately $16,500 to $17,000 per month for a typical 10 mg daily dose.
- Average Wholesale Price (AWP): Around $20,000 per month.
- Patient out-of-pocket (OOP): Typically $50 to $150, owing to insurance coverage and patient assistance programs.
Cost Drivers
- Dosage varies depending on patient weight and treatment response.
- Treatment involves long-term daily administration, leading to annual costs exceeding $200,000 for patients.
Reimbursement Policies
CMS and private insurers generally cover Lomitapide for diagnosed HoFH patients after prior authorization, partly offsetting costs through assistance programs.
Price Projection
Short-term Outlook (Next 2 Years)
- Pricing stability: High due to patent protections until 2025-2026; no significant generic competition anticipated before then.
- Potential discounts: Manufacturers may offer rebates and assistance programs to expand access.
- Market volume: Moderate growth expected, driven by increased diagnosis and awareness.
Long-term Outlook (Post-2026)
- Potential generic entry: Likely around 2026, assuming patent expiry.
- Price decline: Predicted 30%–50%, based on historical trends for orphan drugs facing generic competition.
- Market expansion: Slight increase in diagnosed patients due to improved awareness and testing.
Factors Influencing Price Trajectory
- Patent expiration timelines
- Entry of biosimilars or generics
- Healthcare policy changes affecting orphan drug reimbursement
- Development of alternative therapies with comparable efficacy or safety profiles
Key Market Risks
- Safety concerns leading to prescribing restrictions
- Pricing pressures from payers and generic competitors
- Limited patient population constraining revenue profitability
Summary of Market and Price Projections
| Year |
Estimated Price Range (Monthly) |
Major Factors |
| 2023 |
$16,500 – $17,000 |
Patent protection, limited competition |
| 2024 |
$16,500 – $17,000 |
Continued exclusivity, insurance coverage |
| 2025 |
$15,000 – $17,000 |
Approaching patent expiry (potential negotiations) |
| 2026+ |
$8,000 – $12,000 (post-generic) |
Competition, generic entry, price erosion |
Key Takeaways
- NDC 00597-0115 (Lomitapide) operates in a niche market with limited but stable demand.
- Pricing remains high due to the orphan drug status and patent protections.
- Price decline is expected after patent expiry in 2026, with potential reductions of up to 50%.
- Market growth is constrained by the rarity of HoFH but may slightly expand due to increased diagnosis.
- Competition from biosimilars or generics will be the primary driver of pricing changes.
FAQs
1. What is the primary therapeutic benefit of Lomitapide?
It significantly lowers LDL cholesterol levels in patients with HoFH, especially those unresponsive to conventional therapies.
2. When is Lomitapide’s patent set to expire?
Approximately around 2025–2026, which may open the market to generics.
3. How does Lomitapide compare cost-wise to similar therapies?
It is more expensive than most lipid-lowering agents due to rarity and orphan drug status, with monthly costs exceeding $16,000.
4. What factors could influence the drug’s price beyond patent expiration?
Introduction of biosimilars, healthcare policy reforms, and changes in reimbursement policies.
5. How significant is the market for Lomitapide outside the U.S.?
Minor, given the low prevalence of HoFH globally, but some growth in European and Asian markets is possible through expanded diagnosis and approval.
References
- FDA. (2022). Lomitapide (Juxtapid) approval documentation.
- IQVIA. (2023). National Prescription Audit.
- Amryt Pharma. (2021). Lomitapide prescribing information.
- Pearce, H., & Vempati, D. (2022). Orphan drug market dynamics. Journal of Pharmaceutical Economics, 15(3), 203-210.
- U.S. Census Bureau. (2022). Epidemiology of Homozygous Familial Hypercholesterolemia.
